Stockscreener 앱 받기
1.43
5.15%
0.07
시간 외 거래:
1.42
-0.01
-0.70%
전일 마감가:
$1.36
열려 있는:
$1.35
하루 거래량:
2.89M
Relative Volume:
0.91
시가총액:
$147.86M
수익:
$65,300
순이익/손실:
$-84.93M
주가수익비율:
-0.8372
EPS:
-1.708
순현금흐름:
$-83.57M
1주 성능:
+10.85%
1개월 성능:
+115.65%
6개월 성능:
-17.34%
1년 성능:
-48.00%
1일 변동 폭
$1.35
$1.43
1주일 범위
$1.22
$1.44
52주 변동 폭
$0.5632
$2.9789
Inovio Pharmaceuticals Inc Stock (INO) Company Profile
명칭
Inovio Pharmaceuticals Inc
전화
(858) 410-3134
주소
660 W. GERMANTOWN PIKE, PLYMOUTH MEETING, PA
Compare INO vs VRTX, REGN, ARGX, MRNA, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
INO
Inovio Pharmaceuticals Inc
|
1.43 | 125.11M | 65,300 | -84.93M | -83.57M | -1.708 |
VRTX
Vertex Pharmaceuticals Inc
|
546.12 | 136.93B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
827.72 | 85.11B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
1,033.15 | 64.95B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
145.55 | 53.23B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
210.02 | 45.38B | 742.00K | -1.37B | -1.07B | -7.0731 |
Inovio Pharmaceuticals Inc Stock (INO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Piper Sandler | Overweight |
| 2024-05-14 | 개시 | Stephens | Overweight |
| 2024-01-25 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2022-11-09 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2022-11-01 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2022-07-19 | 재개 | RBC Capital Mkts | Sector Perform |
| 2022-05-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2022-01-21 | 업그레이드 | BofA Securities | Underperform → Neutral |
| 2021-12-29 | 재개 | Jefferies | Hold |
| 2021-09-10 | 다운그레이드 | BofA Securities | Neutral → Underperform |
| 2021-06-24 | 개시 | Jefferies | Hold |
| 2021-03-23 | 개시 | BofA Securities | Neutral |
| 2021-02-12 | 개시 | Oppenheimer | Outperform |
| 2020-11-17 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-11-10 | 업그레이드 | ROTH Capital | Sell → Neutral |
| 2020-09-28 | 다운그레이드 | Cantor Fitzgerald | Overweight → Neutral |
| 2020-09-28 | 업그레이드 | Maxim Group | Hold → Buy |
| 2020-07-01 | 다운그레이드 | Maxim Group | Buy → Hold |
| 2020-07-01 | 다운그레이드 | ROTH Capital | Neutral → Sell |
| 2020-06-29 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2020-06-26 | 다운그레이드 | Stifel | Buy → Hold |
| 2020-05-21 | 개시 | The Benchmark Company | Buy |
| 2020-04-30 | 다운그레이드 | ROTH Capital | Buy → Neutral |
| 2020-03-13 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2020-03-13 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2019-12-19 | 개시 | ROTH Capital | Buy |
| 2018-02-15 | 재확인 | Maxim Group | Buy |
| 2017-10-18 | 개시 | RBC Capital Mkts | Outperform |
| 2017-09-06 | 개시 | Citigroup | Buy |
| 2017-06-08 | 업그레이드 | Piper Jaffray | Neutral → Overweight |
| 2017-05-24 | 재확인 | Maxim Group | Buy |
| 2017-03-16 | 업그레이드 | Maxim Group | Hold → Buy |
| 2017-03-16 | 다운그레이드 | Piper Jaffray | Overweight → Neutral |
모두보기
Inovio Pharmaceuticals Inc 주식(INO)의 최신 뉴스
Inovio Pharmaceuticals Inc. stock underperforms Friday when compared to competitors - MarketWatch
Inovio (INO) Results Versus Estimates: Profit Per Share Clears Its Benchmark in Latest Trading; Market Response: The Stock Ends Down 6.92%Pre-Earnings Setup - Vinanet
Inovio Pharmaceuticals Inc. stock underperforms Thursday when compared to competitors - MarketWatch
Inovio Pharmaceuticals Company Profile & Introduction - Moomoo
INO, MRNA, NVAX, EBS Jump Overnight: Trump Promises Full Hantavirus Report As Deadly Outbreak Sparks Vaccine Rally - Stocktwits
Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day - MarketWatch
Inovio (INO) Earnings Check: The Available Earnings Metric Delivers a Beat at the Close; Post-Report Move: The Stock Ends Up 4.35% in the Latest ReadingFinancial Data - Vinanet
Q3 EPS Estimate for Inovio Pharmaceuticals Raised by Analyst - MarketBeat
INO Jumps As Inovio Wins Upgrade Ahead Of FDA Decision - timothysykes.com
Inovio Stock Jumps As Jefferies Upgrade Bets On FDA Decision - StocksToTrade
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to "Hold" at Wall Street Zen - MarketBeat
INOVIO Sets Aug. 12 Earnings Update With Business Review - MyChesCo
Inovio Pharmaceuticals Highlights FDA Inspection Completion and INO-3107 Regulatory Progress in Q2 2026 Earnings CallDividend Earnings Report - Vinanet
HC Wainwright Issues Negative Estimate for INO Earnings - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Upgraded to Strong-Buy at Zacks Research - MarketBeat
INO Upgraded by Jefferies -- Price Target Raised to $3.00 - GuruFocus
Piper Sandler Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Maintains Target Price $4 - Moomoo
Jefferies Maintains Inovio Pharmaceuticals(INO.US) With Buy Rating, Raises Target Price to $3 - Moomoo
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target - Investing.com
H.C. Wainwright reiterates Neutral on Inovio stock, $2.50 target By Investing.com - Investing.com Canada
Jefferies upgrades Inovio stock rating on FDA review progress - Investing.com
Inovio Q2 2026 slides: INO-3107 on track for Oct FDA decision - Investing.com Nigeria
Jefferies upgrades Inovio stock rating on FDA review progress By Investing.com - Investing.com Canada
Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Recommendation of "Hold" from Analysts - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO): What Does the Latest Update Mean for Regulatory Progress? - Kalkine Media
H.C. Wainwright Maintains Inovio Pharmaceuticals(INO.US) With Hold Rating, Maintains Target Price $2.5 - Moomoo
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlights: INO-3107 on Track for ... - Yahoo Finance
Inovio Pharmaceuticals Inc (INO) (Q2 2026) Earnings Call Highlig - GuruFocus
Inovio Pharmaceuticals, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Inovio Pharmaceuticals, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:INO) 2026-08-12 - Seeking Alpha
Inovio (INO) Q2 2026 Earnings Call Transcript - The Globe and Mail
Inovio Pharmaceuticals, Inc. (INO) stock price, news, quote and history - Yahoo Finance UK
Inovio Q2 EPS $(0.07) beats $(0.22) estimate; loss narrows 74% - scanx.trade
Inovio Pharmaceuticals Q2 Earnings Call Highlights - MarketBeat
Inovio Pharmaceuticals (NASDAQ:INO) Releases Quarterly Earnings Results, Beats Expectations By $0.15 EPS - MarketBeat
Earnings call transcript: Inovio narrows Q2 2026 loss as INO-3107 nears FDA date - Investing.com
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Q2 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
Inovio: Q2 Earnings Snapshot - marketscreener.com
BRIEF-Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million - TradingView
INOVIO Reports Second Quarter 2026 Financial Results and Recent Business Highlights - Yahoo Finance
Adage Capital (INO) discloses 3.43M Inovio shares via warrants in 13G/A - Stock Titan
Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri - AOL.com
Inovio Pharmaceuticals (NASDAQ:INO): What Could Today’s pipeline focus and funding discipline Update Reveal? - Kalkine Media
Inovio Pharmaceuticals Inc expected to post a loss of 22 cents a shareEarnings Preview - TradingView
INO INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announce - The National Law Review
INO SHAREHOLDER NOTICE: Faruqi & Faruqi, LLP Reminds Inovio Pharm - The National Law Review
Inovio Pharmaceuticals Inc Annual Shareholders Meeting Transcript - GuruFocus
Q1 2026 Inovio Pharmaceuticals Inc Earnings Call Transcript - GuruFocus
RA Capital reports 10.67M-share Inovio (NASDAQ: INO) stake capped at 9.99% - Stock Titan
Inovio Pharmaceuticals (INO.US) will release its earnings report after market close on August 12. - Moomoo
Inovio Pharmaceuticals Inc (INO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.86%
0.31%
자본화:
|
볼륨(24시간):